Broken String Biosciences Appoints Steve Becker as Chief Commercial Officer

Autor: Broken String Biosciences

Publikováno v: Business Wire (English). 07/24/2024.

Broken String Biosciences Appoints Gavin Burns as Vice President of Quality and Operations

Autor: Broken String Biosciences

Publikováno v: Business Wire (English). 11/22/2023.

Broken String Biosciences Strengthens Senior Leadership Team to Accelerate Product Development and Commercialization

Autor: Broken String Biosciences

Publikováno v: Business Wire (English). 10/02/2023.

USP50 suppresses alternative RecQ helicase use and deleterious DNA2 activity during replication.

Autor: Mackay HL; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Stone HR; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK.; CCTT-C Cancer Research UK, Clinical trials unit, Sir Robert Aitken building, College of Medicine and Health, University of Birmingham, Birmingham, B15 2TT, UK., Ronson GE; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Ellis K; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK.; School of Chemical, Materials and Biological Engineering, University of Sheffield, Mappin Street, Sheffield, S1 3JD, UK., Lanz A; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Aghabi Y; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Walker AK; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Starowicz K; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK.; Adthera Bio, Lyndon House, 62 Hagley Road, Birmingham, B16 8PE, UK., Garvin AJ; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK.; SUMO Biology Lab, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK., Van Eijk P; Broken String Biosciences Ltd., BioData Innovation Centre, Unit AB3-03, Level 3, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1DR, UK.; Division of Cancer & Genetics School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK., Koestler SA; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Anthony EJ; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Piberger AL; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Chauhan AS; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Conway-Thomas P; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Vaitsiankova A; Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, BN1 9RQ, UK.; Department of Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., Vijayendran S; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK.; University Hospital Birmingham N.H.S. Foundation Trust, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham, B15 2TH, UK., Beesley JF; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Petermann E; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Brown EJ; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 421 Curie Boulevard PA, 19104-6160, USA., Densham RM; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Reed SH; Broken String Biosciences Ltd., BioData Innovation Centre, Unit AB3-03, Level 3, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1DR, UK.; Division of Cancer & Genetics School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK., Dobbs F; Broken String Biosciences Ltd., BioData Innovation Centre, Unit AB3-03, Level 3, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1DR, UK.; Division of Cancer & Genetics School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK., Saponaro M; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Morris JR; Birmingham Centre for Genome Biology and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK. j.morris.3@bham.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2024 Sep 16; Vol. 15 (1), pp. 8102. Date of Electronic Publication: 2024 Sep 16.

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.

Autor: Fletcher CE; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, London, UK. claire.fletcher07@imperial.ac.uk., Deng L; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, London, UK., Orafidiya F; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, London, UK., Yuan W; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK., Lorentzen MPGS; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, London, UK., Cyran OW; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, London, UK., Varela-Carver A; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, London, UK., Constantin TA; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, London, UK., Leach DA; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, London, UK., Dobbs FM; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, UK.; Broken String Biosciences, Unit AB303, Level 3, BioData Innovation Centre, Wellcome Genome Campus, Hinxton, Cambridge, UK., Figueiredo I; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK., Gurel B; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK., Parkes E; Institute for Radiation Oncology, Department of Oncology, University of Oxford, London, UK., Bogdan D; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK., Pereira RR; Translational Oncogenomics, Manchester Cancer Research Centre and Cancer Research UK Manchester Institute, Manchester, UK.; Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK., Zhao SG; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA., Neeb A; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK., Issa F; Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Hester J; Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Kudo H; Section of Pathology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK., Liu Y; Veracyte, Inc., San Diego, CA, USA., Philippou Y; Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK., Bristow R; Translational Oncogenomics, Manchester Cancer Research Centre and Cancer Research UK Manchester Institute, Manchester, UK.; Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.; Christie NHS Foundation Trust, Manchester, UK., Knudsen K; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; American Cancer Society and American Cancer Society Cancer Action Network, Washington DC, USA., Bryant RJ; Institute for Radiation Oncology, Department of Oncology, University of Oxford, London, UK., Feng FY; Departments of Urology and Radiation Oncology, University of California San Francisco, San Francisco, CA, USA., Reed SH; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, UK., Mills IG; Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.; Patrick G Johnston Centre for Cancer Research, Queen's University of Belfast, Belfast, UK.; Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., de Bono J; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK., Bevan CL; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, London, UK.

Publikováno v: Molecular cancer [Mol Cancer] 2022 Mar 22; Vol. 21 (1), pp. 82. Date of Electronic Publication: 2022 Mar 22.